Overview

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Status:
Active, not recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of KHK4827 in patients with systemic sclerosis who have moderate to severe skin thickening
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.
Treatments:
Brodalumab